newsfilter
← Latest News
GlobeNewswire·

Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones

  • Can-Fite BioPharma Ltd. will participate in BIO-Europe 2026 in Cologne, Germany, from November 9–11, with digital sessions scheduled for November 17–18.
  • Dr. Sari Fishman, Vice President of Business Development, will lead discussions on licensing, co-development, commercialization, & strategic transactions.
  • Namodenoson showed positive final Phase IIa results for pancreatic cancer at ESMO 2026, demonstrating favorable safety & encouraging exploratory survival findings.
  • Namodenoson is in an ongoing pivotal Phase III study for advanced hepatocellular carcinoma (HCC), with interim analysis planned after observing longer-than-anticipated blinded overall survival.
  • Piclidenoson has reached its prespecified interim analysis stage in a pivotal Phase III program for psoriasis, with results expected in Q1 2027.
  • Namodenoson is advancing in a Phase IIb program for MASH, while Piclidenoson continues development for Lowe Syndrome supported by a collaboration with Fondazione Telethon.
  • A Eurasian patent allowance recently strengthened for Lowe Syndrome & Dent disease 2 expands Can-Fite's intellectual property protection.
  • The company has secured multiple regional licensing agreements generating approximately $20 million in upfront & milestone payments to date.
  • Can-Fite's lead candidates include Piclidenoson (psoriasis), Namodenoson (liver cancer, pancreatic cancer, MASH), & CF602 (erectile dysfunction), with an excellent safety profile across over 1,600 patients.
  • Namodenoson holds Orphan Drug Designation in the U.S. & Europe, plus Fast Track Designation from the FDA for HCC as a second-line treatment.
  • The company aims to leverage its clinical data & patent portfolio to accelerate development & expand global commercialization opportunities through new partnerships.